Product/Service

Sensor-Enhanced eCOA: Obesity And Weight Management

Source: Ametris
obesity-clinical-trials-GettyImages-1454588173

Sensor-enhanced eCOA (SEE) combines the patient-reported outcomes you already collect through eCOA with continuous data from wearable sensors, designed and delivered together by one partner.

Patients tell you how they feel and function; sensors show how they move and sleep in daily life, every day between visits. Together, they give you multiple lines of evidence on the impact of treatment in patients’ daily lives.

Same Weight Loss.
A Stronger Story.

Show whether weight loss is changing how patients live, with patient-reported outcomes and continuous activity and sleep data in one obesity study.

Weight change remains the primary endpoint in obesity trials, and patient-reported outcomes capture how patients feel and function day to day. Sensor-enhanced eCOA adds continuous activity and sleep data from the ActiGraph LEAP wearable, captured at home between visits. Together, they give you multiple lines of evidence of genuine behavioral change alongside weight loss:

  • Converging Evidence

Weight, PROs, activity and sleep moving together build a more differentiated efficacy story for regulators and payers.

  • Your Design Stays Intact

Physical activity and sleep run as an exploratory layer, and your primary endpoints and statistical plan are untouched.

  • One Partner

Signant and Ametris design eCOA and sensor measures together, from protocol to submission.

SEE the Full Picture

The weight scale alone can't show whether treatments are associated with real behavioral change and real-world impacts. Adding continuous physical activity and sleep data shows whether weight loss is associated with patients moving more or sleeping better, completing the picture.

Our Expertise

  • 22 obesity and metabolic trials delivered by Ametris
  • Over 90% wearable adherence in trials of 12+ months
  • DECODE Obesity, an Ametris-led initiative with Eli Lilly, Novo Nordisk, Roche and AstraZeneca

DECODE Obesity: Measuring What the Scale Can’t

With Lilly, Novo Nordisk, Roche, AbbVie, and AstraZeneca, we’re building the evidence for activity, function and sleep measures that go beyond weight loss. Learn More

Obesity Trials: Measuring Beyond Weight Loss

We help obesity sponsors measure how patients move and sleep, using passive wearables, so you can show benefits beyond weight loss. Learn More